Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Biliary Tract Cancer-01
2023-508057-19-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 29
01
Overview
Phase 3, randomised trial in biliary cancer comparing Trastuzumab deruxtecan + rilvegostomig, Trastuzumab deruxtecan monotherapy and Gemcitabine + cisplatin + durvalumab (3 arms). Planned start Sep 2025; status: authorised.
02
Drugs
trastuzumab deruxtecanrilvegostomigdurvalumabgemcitabinecisplatin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on 2023-508057-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508057-19-00.